Search results for "vaccine."

showing 10 items of 789 documents

The relevance for Public Health of the mid-term and interim analyses of seasonal influenza vaccination effectiveness

2019

Worldwide, influenza is commonly recognized as a respiratory virus that causes a high number of deaths every year, especially among elderly adults and people with chronic illnesses. In order to reduce morbidity and mortality, many countries have implemented, in the last decades, universal influenza vaccination programs with special attention on groups at increased risk of developing the disease, such as pregnant women, children aged 6–59 months, elderly adults and individuals with specific chronic medical conditions. In real-world conditions, observational (nonrandomized) studies on vaccine effectiveness (VE) could measure,the risk reduction of contracting a disease and are considered the g…

medicine.medical_specialtybusiness.industryPublic healthsurveillance networktest-negative designinfluenza vaccine effectiveneSettore MED/42 - Igiene Generale E ApplicataTerm (time)VaccinationSeasonal influenzaVirologyEnvironmental healthInterimmedicineinfluenza viruseRelevance (information retrieval)influenza epidemicbusinesslaboratory confirmed case
researchProduct

Vaccinare per HPV: non solo le adolescenti e non solo profilassi. Review e position paper dell'Italian HPV Study Group (IHSG)

2020

HPV vaccination has been introduced in clinical practice in recent years and represents the most effective strategy of primary prevention of cervical carcinoma and of female genital preneoplastic conditions. One of the major issues of the subject is represented by vaccination coverage of the target population. Since its introduction, HPV vaccine efficacy has been progressively demonstrated also towards extragenital HPV-correlated conditions and in males too. Moreover, even subjects of older age groups or subjects who already had HPV infections have been demonstrated to received benefits from vaccination, due to improvements of their immunological response. Recently, vaccine efficacy has als…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentvirus diseasesObstetrics and GynecologyHpv vaccinationVaccine efficacyfemale genital diseases and pregnancy complicationsVaccinationInternal medicineVaccination coverageCervical carcinomamedicinePosition paperSex organbusinessAdjuvantMinerva Ginecologica
researchProduct

Evaluation of the Burden of HPV-Related Hospitalizations as a Useful Tool to Increase Awareness: 2007–2017 Data from the Sicilian Hospital Discharge …

2020

In light of the implementation of human papillomavirus (HPV) prevention strategies, epidemiological studies in different geographical areas are required in order to assess the impact of HPV-related diseases. The purpose of the present study was to describe the burden of HPV-related hospitalizations in Sicily. A retrospective observational study estimated 43,531 hospitalizations attributable to HPV from 2007 to 2017. During the observed period, there was a decrease for all HPV-related conditions with a higher reduction, among neoplasms, for cervical cancer (annual percent change (APC) = &minus

medicine.medical_specialtycervical cancerImmunologyimpact evaluationcervical cancer screeninglcsh:MedicineCervical cancer screeningArticleburdenscreening effectiveness03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoveryCervical carcinomaEpidemiologyHospital dischargeScreening effectiveneMedicinePharmacology (medical)030212 general & internal medicineHPV vaccinePharmacologyCervical cancerHPV-related diseasevaccine effectivenessbusiness.industrylcsh:Rvirus diseasesRetrospective cohort studymedicine.diseaseVaccine introductionhospitalization rateAnnual Percent Changefemale genital diseases and pregnancy complicationsInfectious DiseasesItaly030220 oncology & carcinogenesisbusinessVaccines
researchProduct

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.

1998

The disappointing clinical results of cancer immunotherapy of the past few decades have not diminished the optimism about the potential of the new generation of immunotherapeutic strategies towards treatment of malignant disease. Tremendous progress has been made over recent years in unveiling the molecular basis of antigen presentation and recognition by cytotoxic T lymphocytes (CTL). The molecular concepts that have emerged from these studies have led to the design of novel anticancer vaccines and CTL-based immunotherapeutics. This review is to highlight the current molecular insights of antigen presentation and CTL recognition/activation, and their impact on the rational design of therap…

medicine.medical_treatmentAntigen presentationMolecular Sequence Datachemical and pharmacologic phenomenaCancer VaccinesImmune systemCancer immunotherapyNeoplasmsDrug DiscoverymedicineCytotoxic T cellAnimalsHumansAmino Acid SequenceGenetics (clinical)Antigen Presentationbusiness.industryImmunotherapyT lymphocyteMolecular medicineCTL*ImmunologyMolecular MedicineImmunotherapybusinessT-Lymphocytes CytotoxicJournal of molecular medicine (Berlin, Germany)
researchProduct

Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer

2013

Background & Aims Pancreatic ductal adenocarcinoma (PDA) is an aggressive tumor, and patients typically present with late-stage disease; rates of 5-year survival after pancreaticoduodenectomy are low. Antibodies against α-enolase (ENO1), a glycolytic enzyme, are detected in more than 60% of patients with PDA, and ENO1-specific T cells inhibit the growth of human pancreatic xenograft tumors in mice. We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolongs survival of mice that spontaneously develop autochthonous, lethal pancreatic carcinomas. Methods We injected and electroporated a plasmid encoding ENO1 (or a control plasmid) into Kras G12D /Cre (KC) mice …

medicine.medical_treatmentDNA Vaccine; Enolase; Parnceratic cancer; Transgeneic miceEnolasegenetically engineered miceceEnzyme-Linked Immunosorbent AssayTransgeneic miceDNA vaccination03 medical and health sciencesMice0302 clinical medicineImmune systemPancreatic cancerGenetic modelmedicineVaccines DNADNA VaccineAnimalsSurvival rate030304 developmental biology0303 health sciencesImmunity CellularHepatologybiologyENO.1; DNA Vaccine; genetically engineered miceceVaccinationGastroenterologyParnceratic cancerImmunotherapyNeoplasms Experimentalmedicine.diseaseImmunohistochemistryMice Mutant Strains3. Good healthPancreatic NeoplasmsSurvival RateSettore BIO/18 - GeneticaTumor progression030220 oncology & carcinogenesisPhosphopyruvate HydrataseImmunologybiology.proteinAntibodyENO.1Carcinoma Pancreatic Ductal
researchProduct

Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.

2002

Mutations and aberrant expression of the p53 tumor suppressor protein are the most frequent molecular alterations in human malignancy. Peptides derived from the wild-type (wt) p53 protein and presented by major histocompatibility complex (MHC) molecules for T lymphocyte recognition are believed to serve as universal tumor-associated antigens for cancer immunotherapy. We studied the immunogeneicity of a recombinant replication-defective adenoviral vector encoding human full-length wt p53 (rAd/hup53) in human leukocyte antigen (HLA)-A2K(b)-transgenic (Tg) mice and man. The generation of p53 epitope-specific cytotoxic T lymphocytes (CTLs) in p53-proficient and p53-deficient A2K(b)-Tg mice was …

medicine.medical_treatmentGenetic VectorsEpitopes T-LymphocyteMice TransgenicPilot ProjectsHuman leukocyte antigenBiologyMajor histocompatibility complexCancer VaccinesEpitopeAdenoviridaeMiceImmune systemCancer immunotherapyAntigenSpecies SpecificityNeoplasmsHLA-A2 AntigenGeneticsmedicineCytotoxic T cellAnimalsHumansTreatment FailureMolecular BiologyT lymphocyteGenetic TherapyGenes p53Self ToleranceImmunologybiology.proteinMolecular MedicineTumor Suppressor Protein p53T-Lymphocytes CytotoxicGene therapy
researchProduct

More about genetically modified tumour vaccines

1998

medicine.medical_treatmentGenetic enhancementGene Transfer TechniquesMEDLINEImmunotherapy ActiveGenetic TherapyImmunotherapyBiologyCancer VaccinesGenetically modified organismGeneticsmedicineCancer researchCytokinesHumansMolecular MedicineMolecular BiologyGene Therapy
researchProduct

Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.

2014

Multivalent synthetic vaccines were obtained by solid-phase synthesis of tumor-associated MUC1 glycopeptide antigens and their coupling to a Pam3 Cys lipopeptide through click reactions. These vaccines elicited immune responses in mice without the use of any external adjuvant. The vaccine containing four copies of a MUC1 sialyl-TN antigen showed a significant cluster effect. It induced in mice prevailing IgG2a antibodies, which bind to MCF-7 breast tumor cells and initiate the killing of these tumor cells by activation of the complement-dependent cytotoxicity complex.

medicine.medical_treatmentLipoproteinsEpitopes T-LymphocyteApoptosisCancer VaccinesCatalysisAntibodieschemistry.chemical_compoundMiceImmune systemAntigenmedicineAnimalsHumansAmino Acid Sequenceskin and connective tissue diseasesCytotoxicityMUC1Mice Inbred BALB CbiologyMucin-1GlycopeptidesLipopeptideGeneral ChemistryCombinatorial chemistryGlycopeptidechemistrybiology.proteinCancer researchMCF-7 CellsClick ChemistryRabbitsAntibodyAdjuvantAngewandte Chemie (International ed. in English)
researchProduct

Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and prot…

2006

ABSTRACTRotavirus (RV) is the main etiological agent of severe gastroenteritis in infants, and vaccination seems the most effective way to control the disease. Recombinant rotavirus-like particles composed of the viral protein 6 (VP6) and VP2 (2/6-VLPs) have been reported to induce protective immunity in mice when administered by the intranasal (i.n.) route. In this study, we show that administration of 2/6-VLPs by the intrarectal (i.r.) route together with either cholera toxin (CT) or a CpG-containing oligodeoxynucleotide as the adjuvant protects adult mice against RV infection. Moreover, when CT is used, RV shedding in animals immunized by the i.r. route is even reduced in comparison with…

medicine.medical_treatmentMESH : Cytokinesanimal diseasesMESH : Oligodeoxyribonucleotidesmedicine.disease_causeAntibodies ViralImmunoglobulin GMiceIntestinal mucosaMESH: RectumRotavirusMESH : FemaleMESH: AnimalsViralIntestinal MucosaInbred BALB C0303 health sciencesMice Inbred BALB CMESH: CytokinesMESH : Cholera ToxinMESH : Immunoglobulin A SecretoryMESH: Rotavirus Infections3. Good healthMESH : Rotavirus VaccinesVaccinationmedicine.anatomical_structureOligodeoxyribonucleotides[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH : RectumMESH: Intestinal MucosaCytokinesMESH: VirionMESH: ImmunizationFemaleAdjuvantMESH : Antibodies ViralCholera ToxinImmunologyMESH: Mice Inbred BALB CSpleenchemical and pharmacologic phenomenaBiologyMicrobiologyMESH : Intestinal Mucosa[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH: Rotavirus VaccinesRotavirus InfectionsAntibodies03 medical and health sciencesImmune systemVirologyVaccines and Antiviral AgentsMESH : MicemedicineMESH : Rotavirus InfectionsMESH : VirionAnimalsMESH: MiceMESH : Mice Inbred BALB CMESH: Cholera Toxin030304 developmental biology030306 microbiologyRotavirus VaccinesRectumVirionMESH : Immunizationbiochemical phenomena metabolism and nutritionSecretoryVirologyImmunoglobulin AMESH: Immunoglobulin A SecretoryImmunizationInsect ScienceImmunologyImmunoglobulin A Secretorybiology.proteinMESH: OligodeoxyribonucleotidesbacteriaImmunizationMESH : AnimalsMESH: FemaleMESH: Antibodies Viral
researchProduct

CpG-Loaded Multifunctional Cationic Nanohydrogel Particles as Self-Adjuvanting Glycopeptide Antitumor Vaccines

2014

Self-adjuvanting antitumor vaccines by multifunctional cationic nanohydrogels loaded with CpG. A conjugate consisting of tumor-associated MUC1-glycopeptide B-cell epitope and tetanus toxin T-cell epitope P2 is linked to cationic nanogels. Oligonucleotide CpG complexation enhances toll-like receptor (TLR) stimulated T-cell proliferation and rapid immune activation. This co-delivery promotes induction of specific MUC1-antibodies binding to human breast tumor cells without external adjuvant.

medicine.medical_treatmentMolecular Sequence DataBiomedical EngineeringPharmaceutical ScienceEnzyme-Linked Immunosorbent Assaymedicine.disease_causeCancer VaccinesHydrogel Polyethylene Glycol DimethacrylateEpitopeBiomaterialsAdjuvants ImmunologicCationsmedicineAnimalsHumansAmino Acid SequenceReceptorMice Inbred BALB COligonucleotideToxinChemistryGlycopeptidesGlycopeptideOligodeoxyribonucleotidesCpG siteImmunologyCancer researchNanoparticlesAdjuvantConjugateAdvanced Healthcare Materials
researchProduct